|
Market Closed -
Sao Paulo
03:38:37 06/10/2026 HKT
|
5-day change | 1st Jan Change | ||
| 78.80 BRL | -10.74% |
|
-8.61% | +0.72% |
| 09-28 | UBS Raises Vertex Pharmaceuticals Price Target to $615 From $585, Maintains Buy Rating | MT |
| 09-23 | TD Cowen Adjusts PT on Vertex Pharmaceuticals to $550 From $525, Maintains Buy Rating | MT |
| Market Cap | 128B 639B 114B 106B 96.78B 182B 12,320B 184B 1,283B 499B 6,286B 480B 470B 20,192B | P/E 2026 * |
51.7x | P/E 2027 * | 27.3x |
|---|---|---|---|---|---|
| Enterprise Value | 122B 611B 109B 102B 92.59B 174B 11,786B 176B 1,228B 477B 6,014B 459B 450B 19,317B | EV / Sales 2026 * |
9.24x | EV / Sales 2027 * | 8.13x |
| Free-Float |
99.79% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Vertex Pharmaceuticals Incorporated
| 1 day | -10.74% | ||
| 1 week | -8.61% | ||
| Current month | -8.22% | ||
| 1 month | -6.41% | ||
| 3 months | -6.94% | ||
| 6 months | +13.14% | ||
| Current year | +0.72% |
| 1 week | 77.53 |  | 85.86 |
| 1 month | 77.53 | | 86.22 |
| Current year | 65.18 | | 89.01 |
| 1 year | 65.18 | | 89.01 |
| 3 years | 52.29 | | 93.56 |
| 5 years | 30.88 | | 93.56 |
| 10 years | 20.29 | | 93.56 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 53 | 01/04/2020 | |
Charles Wagner
DFI | Director of Finance/CFO | 57 | 10/04/2019 |
Sean Daughtry
CTO | Chief Tech/Sci/R&D Officer | - | 01/03/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Bruce Sachs
BRD | Director/Board Member | 66 | 01/01/1998 |
Jeffrey Leiden
CHM | Chairman | 70 | 01/05/2012 |
Sangeeta Bhatia
BRD | Director/Board Member | 57 | 18/06/2015 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -10.74% | -8.61% | - | - | 128B | |
| +0.02% | -3.41% | +36.11% | +115.09% | 1,019B | |
| -1.21% | -6.74% | +34.08% | +62.64% | 617B | |
| +1.12% | +0.54% | +13.62% | +79.94% | 464B | |
| -3.30% | -6.21% | +56.45% | +36.58% | 356B | |
| +0.93% | -3.16% | +21.65% | +43.02% | 333B | |
| +0.12% | -2.77% | +10.70% | +32.97% | 267B | |
| -0.89% | -6.28% | -7.00% | +8.01% | 244B | |
| -0.01% | -2.81% | +35.28% | +51.82% | 218B | |
| -0.08% | -4.17% | +28.34% | +93.51% | 179B | |
| Average | -1.35% | -3.54% | +25.47% | +58.17% | 410.8B | |
| Weighted average by Cap. | -0.56% | -3.54% | +28.50% | +70.11% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 13.25B 66.15B 11.81B 11B 10.02B 18.88B 1,276B 19.02B 133B 51.68B 651B 49.73B 48.66B 2,091B | 14.55B 72.66B 12.97B 12.08B 11.01B 20.73B 1,401B 20.89B 146B 56.76B 715B 54.63B 53.44B 2,297B |
| Net income | 2.54B 12.66B 2.26B 2.11B 1.92B 3.61B 244B 3.64B 25.43B 9.89B 125B 9.52B 9.31B 400B | 4.84B 24.15B 4.31B 4.02B 3.66B 6.89B 466B 6.94B 48.51B 18.87B 238B 18.16B 17.76B 763B |
| Net Debt | -5.54B -27.67B -4.94B -4.6B -4.19B -7.9B -534B -7.96B -55.59B -21.62B -272B -20.81B -20.36B -875B | -9.58B -47.83B -8.54B -7.95B -7.25B -13.65B -922B -13.75B -96.09B -37.37B -471B -35.96B -35.18B -1,512B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/09/26 | R$85.86 | -0.42% | 611 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- VRTX Stock
- VRTX34 Stock
Select your edition
All financial news and data tailored to specific country editions
